Please login to the form below

Not currently logged in
Email:
Password:

Almirall earnings hit by generics

Spanish pharmaceutical firm Almirall has said price erosion and generic competition is responsible for a fall in earnings in its first half financial report

Spanish pharmaceutical company Almirall has reported an 18 per cent decline in first half pre-tax earnings to €11.2m, citing price erosion and generic competition.

Its net sales fell by 9 per cent to €426.8m in the six month period to June 30. The company said that there was a stronger growth in European sales, which rose by 3.3 per cent, while sales in Africa, America and Asia increased by 3 per cent.

Eduardo Sanchiz, Almirall chief executive, said: "The first half of the year reflects a material improvement in P&L trends versus the first quarter and we maintain solid financial position and steady free cash flow generation that provides strategic flexibility."

The company said that cost discipline and savings were a continued priority for 2011, but put guidance for the rest of the year on hold.

28th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics